ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 52 filers reported holding ADC THERAPEUTICS SA in Q4 2020. The put-call ratio across all filers is 5.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,297 | -15.4% | 22,629 | +102.7% | 0.00% | – |
| Q2 2023 | $24,002 | +29.8% | 11,164 | +17.7% | 0.00% | – |
| Q1 2023 | $18,490 | -26.0% | 9,482 | +44.0% | 0.00% | – |
| Q4 2022 | $25,000 | 0.0% | 6,584 | +25.2% | 0.00% | – |
| Q3 2022 | $25,000 | -43.2% | 5,257 | -4.1% | 0.00% | – |
| Q2 2022 | $44,000 | -6.4% | 5,483 | +68.8% | 0.00% | – |
| Q1 2022 | $47,000 | +840.0% | 3,248 | +1270.5% | 0.00% | – |
| Q4 2021 | $5,000 | -44.4% | 237 | -30.7% | 0.00% | – |
| Q3 2021 | $9,000 | 0.0% | 342 | -12.8% | 0.00% | – |
| Q2 2021 | $9,000 | +80.0% | 392 | +116.6% | 0.00% | – |
| Q1 2021 | $5,000 | -16.7% | 181 | 0.0% | 0.00% | – |
| Q4 2020 | $6,000 | +20.0% | 181 | +9.7% | 0.00% | – |
| Q3 2020 | $5,000 | -37.5% | 165 | -7.8% | 0.00% | – |
| Q2 2020 | $8,000 | – | 179 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $4,555,066 | 2.69% |
| Blue Owl Capital Holdings LP | 733,568 | $2,816,901 | 1.20% |
| Redmile Group, LLC | 7,590,849 | $29,148,860 | 1.19% |
| AlphaCentric Advisors LLC | 297,500 | $1,142,400 | 1.13% |
| Prosight Management, LP | 463,310 | $1,779,110 | 0.97% |
| GCM Grosvenor Holdings, LLC | 735,471 | $2,824,209 | 0.72% |
| Indie Asset Partners, LLC | 93,839 | $360,342 | 0.40% |
| XTX Topco Ltd | 197,635 | $758,918 | 0.16% |
| Eventide Asset Management | 1,879,959 | $7,219,043 | 0.14% |
| Nantahala Capital Management | 243,290 | $934,234 | 0.06% |